FDA Accepts NDA, Grants Priority Review for Rare Disease Therapy With Feb 2027 PDUFA
PVLA sits 96% above its 52-week low of $68.96.
Summary
The FDA accepted Palvella's NDA for QTORIN 3.9% rapamycin gel in microcystic lymphatic malformations and granted Priority Review, with a PDUFA target action date of Feb 28, 2027. The filing rests on Phase 3 SELVA data that hit all six endpoints at p<0.001, and the company reports no drug-related serious adverse events. This follows the completed rolling NDA submission announced August 31 and the Q2 filing that showed $250.6 million in cash — enough to fund a planned H1 2027 US launch if approved. Priority Review shortens the review clock and raises approval visibility for what would be a first-in-disease topical therapy; the stock now has a hard binary date. The remaining swing factors are labeling and pricing, not efficacy. Watch the Feb 28, 2027 PDUFA date.
At the time of this announcement, PVLA was trading at $134.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $68.96 to $161.38. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: Wiseek News.